サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1790236

北米の臨床試験市場規模、シェア、動向分析レポート：フェーズ別、試験設計別、適応症別、サービス別、スポンサー別、国別、セグメント別予測、2025年～2033年

North America Clinical Trials Market Size, Share & Trends Analysis Report By Phase, By Study Design, By Indication, By Indication by Study Design, By Service, By Sponsor, By Country, And Segment Forecasts, 2025 - 2033

出版日
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.78円
北米の臨床試験市場規模、シェア、動向分析レポート：フェーズ別、試験設計別、適応症別、サービス別、スポンサー別、国別、セグメント別予測、2025年～2033年
出版日: 2025年07月07日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

北米の臨床検査市場概要

北米の臨床検査市場規模は2024年に430億3,000万米ドルと推定され、2033年には773億2,000万米ドルに達すると予測され、2025～2033年のCAGRは6.98%で成長します。市場成長の原動力となっているのは、学術研究機関の強固なエコシステム、製薬企業による研究開発資金の拡大、初期から後期にかけての大量の検査をサポートする専門的な開発業務受託機関（CRO）です。

北米の臨床検査市場は、高度に発達した研究インフラと、一貫して臨床開発を優先する世界の製薬、バイオテクノロジー、医療機器企業の集中によって推進されています。メイヨークリニック、MDアンダーソンがんセンター、ハーバード大学医療部など、複数の学術研究センターや病院が存在することが、初期段階の検査における技術革新とパートナーシップを促進しています。さらに、米国FDAなどの規制機関は、治験薬（IND）申請、希少疾病用医薬品の指定、適応検査デザインについて確立された枠組みを提供しており、これが参入障壁を下げ、臨床スケジュールを早めています。

さらに、産業利害関係者、デジタルヘルスイノベーター、患者擁護団体間の協力が増加しています。製薬企業は、自社の研究開発パイプラインを拡大するだけでなく、CROと積極的に提携し、検査デザイン、施設管理、薬事申請を合理化しています。この動向により、スポンサーはデータの完全性や患者の安全性を損なうことなく、スケジュールを早めることができます。同様に、アドボカシー財団や公衆衛生キャンペーンに支えられた患者の意識と教育の高まりは、特に腫瘍や希少疾患などの複雑な領域において、より多くの臨床検査への参加につながっています。連邦政府のガイドラインや多様性の義務に支えられた、より包括的な登録戦略へのシフトは、実世界の集団をよりよく反映した臨床結果を保証しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 北米の臨床検査市場の変数、動向、範囲

  • 市場系統の展望
    • 親市場展望
    • 補助市場展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
    • 市場機会分析
    • 市場課題分析
  • 研究開発費分析
    • 主要スポンサー別R&D投資分析（2021～2024年）
    • ベンチャーキャピタルと政府の資金調達シナリオ
  • 臨床検査設計分析
  • 産業エコシステム分析
  • 技術
  • 価格分析
  • 2024年の臨床検査件数分析
    • 地域別臨床検査総数（2024年）
    • 臨床検査の総数（相別）（2024年）
    • 臨床検査の総数（研究デザイン別）（2024年）
    • 主要適応症別臨床検査総数（2024年）
  • 臨床検査市場分析ツール
    • ポーターのファイブフォース分析
    • SWOT分析によるPESTEL

第4章 北米の臨床検査市場：フェーズ別、推定・動向分析

  • セグメントダッシュボード
  • 北米の臨床検査市場：フェーズ変動分析
  • フェーズ別、2021～2033年
  • フェーズI
  • フェーズII
  • フェーズIII
  • フェーズIV

第5章 北米の臨床検査市場：研究設計別、推定・動向分析

  • セグメントダッシュボード
  • 北米の臨床検査市場：研究設計変動分析
  • 研究設計別、2021～2033年
  • 介入的
  • 観察的
  • 拡大アクセス

第6章 北米の臨床検査市場：適応症別、推定・動向分析

  • セグメントダッシュボード
  • 北米の臨床検査市場：適応症変動分析
  • 適応症別、2021～2033年
  • 自己免疫/炎症
    • 関節リウマチ
    • 多発性硬化症
    • 変形性関節症
    • 過敏性腸症候群（IBS）
    • その他
  • 疼痛管理
    • 慢性疼痛
    • 急性疼痛
  • 腫瘍学
    • 血液がん
    • 固形腫瘍
    • その他
  • 中枢神経系の症状
    • てんかん
    • パーキンソン病（PD）
    • ハンチントン病
    • 脳卒中
    • 外傷性脳損傷（TBI）
    • 筋萎縮性側索硬化症（ALS）
    • 筋肉の再生
    • その他
  • 糖尿病
  • 肥満
  • 心血管疾患
  • その他

第7章 北米の臨床検査市場：研究設計別、適応症推定・動向分析

  • セグメントダッシュボード
  • 北米の臨床検査市場：研究設計変動分析
  • 研究設計別、研究デザイン別、2021～2033年
  • 自己免疫/炎症
    • 介入検査
    • 観察検査
    • 拡大アクセス検査
  • 疼痛管理
    • 介入検査
    • 観察検査
    • 拡大アクセス検査
  • 腫瘍学
    • 介入検査
    • 観察検査
    • 拡大アクセス検査
  • 中枢神経系の症状
    • 介入検査
    • 観察検査
    • 拡大アクセス検査
  • 糖尿病
    • 介入検査
    • 観察検査
    • 拡大アクセス検査
  • 肥満
    • 介入検査
    • 観察検査
    • 拡大アクセス検査
  • 心血管疾患
    • 介入検査
    • 観察検査
    • 拡大アクセス検査
  • その他
    • 介入検査
    • 観察検査
    • 拡大アクセス検査

第8章 北米の臨床検査市場：サービス別、推定・動向分析

  • セグメントダッシュボード
  • 北米の臨床検査市場：サービス変動分析
  • サービス別、2021～2033年
  • プロトコル設計
  • 部位の識別
  • 患者募集
  • ラボサービス
  • 分析検査サービス
  • 臨床検査データ管理サービス
  • その他

第9章 北米の臨床検査市場：スポンサー別、推定・動向分析

  • セグメントダッシュボード
  • 北米の臨床検査市場：スポンサー変動分析
  • スポンサー別、2021～2033年
  • 製薬バイオ医薬品企業
  • 医療機器企業
  • その他

第10章 北米の臨床検査市場：国別、推定・動向分析

  • 国別展望
  • 北米の臨床検査市場：国変動分析
  • 国別、2021～2033年
  • 北米
    • 米国
    • カナダ
    • メキシコ

第11章 競合情勢

  • 企業分類
    • イノベーター
    • マーケットリーダー
    • 新興参入企業
  • 企業市場評価分析、2024年
  • 主要企業プロファイル
    • Pfizer Inc.
    • Merck & Co., Inc.
    • AbbVie Inc.
    • Amgen Inc.
    • Bristol Myers Squibb
    • Gilead Sciences, Inc.
    • Eli Lilly and Company
    • Biogen Inc.
    • Moderna, Inc.
    • Labcorp
    • IQVIA, Inc.
    • Syneos Health
    • PAREXEL International Corporation
    • ICON Plc
    • Thermo Fisher Scientific Inc.
    • Charles River Laboratories International Inc.
    • Medpace Holdings, Inc.
    • Worldwide Clinical Trials
    • Clinipace Inc.
    • Fortrea
  • その他の主要市場参入企業一覧
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 North America Clinical Trials Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 4 North America Clinical Trials Market Estimates and Forecasts, by Phase, 2021 - 2033 (USD Million)
  • Table 5 North America Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 6 North America Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 7 North America Clinical Trials Market Estimates and Forecasts, Indication by Study Design, 2021 - 2033 (USD Million)
  • Table 8 North America Clinical Trials Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 9 North America Clinical Trials Market Estimates and Forecasts, by Sponsor, 2021 - 2033 (USD Million)
  • Table 10 U.S. Clinical Trials Market Estimates and Forecasts, by Phase, 2021 - 2033 (USD Million)
  • Table 11 U.S. Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 12 U.S. Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 13 U.S. Clinical Trials Market Estimates and Forecasts, Indication by Study Design, 2021 - 2033 (USD Million)
  • Table 14 U.S. Clinical Trials Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 15 U.S. Clinical Trials Market Estimates and Forecasts, by Sponsor, 2021 - 2033 (USD Million)
  • Table 16 Canada Clinical Trials Market Estimates and Forecasts, by Phase, 2021 - 2033 (USD Million)
  • Table 17 Canada Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 18 Canada Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 19 Canada Clinical Trials Market Estimates and Forecasts, Indication by Study Design, 2021 - 2033 (USD Million)
  • Table 20 Canada Clinical Trials Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 21 Canada Clinical Trials Market Estimates and Forecasts, by Sponsor, 2021 - 2033 (USD Million)
  • Table 22 Mexico Clinical Trials Market Estimates and Forecasts, by Phase, 2021 - 2033 (USD Million)
  • Table 23 Mexico Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 24 Mexico Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 25 Mexico Clinical Trials Market Estimates and Forecasts, Indication by Study Design, 2021 - 2033 (USD Million)
  • Table 26 Mexico Clinical Trials Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 27 Mexico Clinical Trials Market Estimates and Forecasts, by Sponsor, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Clinical Trials Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Information Procurement
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value Chain-Based Sizing & Forecasting
  • Fig. 7 Market Formulation & Validation
  • Fig. 8 Market Dynamics
  • Fig. 9 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 11 Porter's Five Forces Analysis
  • Fig. 12 PESTEL by SWOT Analysis
  • Fig. 13 North America Phase I Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 14 North America Phase II Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 15 North America Phase III Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 16 North America Phase IV Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 17 North America Interventional Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 18 North America Observational Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 19 North America Expanded Access Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 20 North America Autoimmune/Inflammation Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 21 North America Rheumatoid Arthritis Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 North America Multiple Sclerosis Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 North America Osteoarthritis Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 North America Irritable Bowel Syndrome (IBS) Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 North America Others Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 North America Pain Management Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 North America Chronic Pain Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 North America Acute Pain Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 North America Oncology Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 North America Blood Cancer Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 North America Solid Tumors Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 North America Others Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 North America CNS Conditions Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 North America Epilepsy Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 North America Parkinson's Disease (PD) Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 North America Huntington's Disease Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 North America Stroke Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 North America Traumatic Brain Injury (TBI) Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 North America Amyotrophic Lateral Sclerosis (ALS) Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 North America Muscle Regeneration Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 North America Others Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 North America Diabetes Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 North America Obesity Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 North America Cardiovascular Diseases Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 North America Others Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 North America Autoimmune/Inflammation Interventional Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 North America Autoimmune/Inflammation Observational Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 North America Autoimmune/Inflammation Expanded Access Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 North America Pain Management Interventional Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 North America Pain Management Observational Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 North America Pain Management Expanded Access Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 North America Oncology Interventional Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 North America Oncology Observational Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 North America Oncology Expanded Access Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 North America CNS Conditions Interventional Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 North America CNS Conditions Observational Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 North America CNS Conditions Expanded Access Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 North America Diabetes Interventional Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 North America Diabetes Observational Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 North America Diabetes Expanded Access Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 North America Obesity Interventional Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 North America Obesity Observational Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 North America Obesity Expanded Access Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 North America Cardiovascular Diseases Interventional Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 North America Cardiovascular Diseases Observational Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 North America Cardiovascular Diseases Expanded Access Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 North America Others Interventional Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 North America Others Observational Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 North America Others Expanded Access Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 North America Protocol Designing Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 North America Site Identification Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 North America Patient Recruitment Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 73 North America Laboratory Services Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 North America Analytical Testing Services Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 75 North America Clinical Trial Data Management Services Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 North America Others Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 North America Pharmaceutical & Biopharmaceutical Companies Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 North America Medical Device Companies Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 79 North America Others Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 Country Outlook, 2024 & 2033
  • Fig. 81 US Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 Canada Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 83 Mexico Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
目次
Product Code: GVR-4-68040-202-2

North America Clinical Trials Market Summary

The North America clinical trials market size was estimated at USD 43.03 billion in 2024 and is projected to reach USD 77.32 billion by 2033, growing at a CAGR of 6.98% from 2025 to 2033. The market growth is driven by a robust ecosystem of academic research institutions, growing research and development funding by pharmaceutical companies, and specialized contract research organizations (CROs) that support a high volume of early-to late-phase studies.

The North America clinical trials market is propelled by a highly developed research infrastructure and a concentration of global pharmaceutical, biotechnology, and medical device companies that consistently prioritize clinical development. The presence of several academic research centers and hospitals such as the Mayo Clinic, MD Anderson Cancer Center, and Harvard Medical School is driving the innovation and partnerships in early-stage trials. Moreover, the regulatory agencies such as the U.S. FDA are offering well-established frameworks for Investigational New Drug (IND) applications, Orphan Drug Designations, and adaptive trial designs which is lowering the entry barriers and accelerating the clinical timeline.

Furthermore, increasing collaboration between industry stakeholders, digital health innovators, and patient advocacy groups. Pharmaceutical companies are not only expanding their in-house R&D pipelines but are also actively partnering with CROs to streamline study design, site management, and regulatory submissions. This trend allows sponsors to accelerate timelines without compromising on data integrity or patient safety. Similarly, rising patient awareness and education, often supported by advocacy foundations and public health campaigns has resulted in greater trial participation, particularly in complex areas such as oncology and rare diseases. The shift toward more inclusive enrollment strategies, supported by federal guidelines and diversity mandates, ensures that clinical outcomes better reflect real-world populations.

North America Clinical Trials Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the North America clinical trials market report based on phase, study design, indication, indication by study design, service, sponsor, and country:

  • Phase Outlook (Revenue, USD Million, 2021 - 2033)
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
  • Study Design Outlook (Revenue, USD Million, 2021 - 2033)
  • Interventional Trials
  • Observational Trials
  • Expanded Access Trials
  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Autoimmune/Inflammation
    • Rheumatoid Arthritis
    • Multiple Sclerosis
    • Osteoarthritis
    • Irritable Bowel Syndrome (IBS)
    • Others
  • Pain Management
    • Chronic Pain
    • Acute Pain
  • Oncology
    • Blood Cancer
    • Solid Tumors
    • Others
  • CNS Conditions
    • Epilepsy
    • Parkinson's Disease (PD)
    • Huntington's Disease
    • Stroke
    • Traumatic Brain Injury (TBI)
    • Amyotrophic Lateral Sclerosis (ALS)
    • Muscle Regeneration
    • Others
  • Diabetes
  • Obesity
  • Cardiovascular Diseases
  • Others
  • Indication by Study Design Outlook (Revenue, USD Million, 2021 - 2033)
  • Autoimmune/Inflammation
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Pain Management
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Oncology
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • CNS Conditions
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Diabetes
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Obesity
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Cardiovascular Diseases
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Others
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Protocol Designing
  • Site Identification
  • Patient Recruitment
  • Laboratory Services
  • Analytical Testing Services
  • Clinical Trial Data Management Services
  • Others
  • Sponsor Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical & Biopharmaceutical Companies
  • Medical Device Companies
  • Others
  • Country Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Value chain based analysis (Model 2)
    • 1.7.3. Multivariate Analysis (Model 3)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. North America Clinical Trials Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. R&D Spending Analysis
    • 3.3.1. R&D Investment Analysis, by Key Sponsors (2021-2024)
    • 3.3.2. Venture Capital & Government Funding Scenario
  • 3.4. Clinical Trials Design Analysis
  • 3.5. Industry Ecosystem Analysis
  • 3.6. Technology Landscape
  • 3.7. Pricing Analysis
  • 3.8. Clinical Trial Volume Analysis, 2024
    • 3.8.1. Total Number of Clinical Trials, By Region (2024)
    • 3.8.2. Total Number of Clinical Trials, By Phase (2024)
    • 3.8.3. Total Number of Clinical Trials, By Study Design (2024)
    • 3.8.4. Total Number of Clinical Trials, By Key Indication (2024)
  • 3.9. Clinical Trials Market Analysis Tools
    • 3.9.1. Porter's Five Forces Analysis
    • 3.9.2. PESTEL by SWOT Analysis

Chapter 4. North America Clinical Trials Market: Phase Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. North America Clinical Trials Market: Phase Movement Analysis
  • 4.3. North America Clinical Trials Market Estimates and Forecasts, by Phase, 2021 - 2033 (USD Million)
  • 4.4. Phase I
    • 4.4.1. Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Phase II
    • 4.5.1. Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Phase III
    • 4.6.1. Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Phase IV
    • 4.7.1. Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. North America Clinical Trials Market: Study Design Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. North America Clinical Trials Market: Study Design Movement Analysis
  • 5.3. North America Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • 5.4. Interventional
    • 5.4.1. Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Observational
    • 5.5.1. Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Expanded Access
    • 5.6.1. Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. North America Clinical Trials Market: Indication Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. North America Clinical Trials Market: Indication Movement Analysis
  • 6.3. North America Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • 6.4. Autoimmune/Inflammation
    • 6.4.1. Autoimmune/Inflammation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.2. Rheumatoid Arthritis
      • 6.4.2.1. Rheumatoid Arthritis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Multiple Sclerosis
      • 6.4.3.1. Multiple Sclerosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Osteoarthritis
      • 6.4.4.1. Osteoarthritis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.5. Irritable Bowel Syndrome (IBS)
      • 6.4.5.1. Irritable Bowel Syndrome (IBS) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.6. Others
      • 6.4.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Pain Management
    • 6.5.1. Pain Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. Chronic Pain
      • 6.5.2.1. Chronic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Acute Pain
      • 6.5.3.1. Acute Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Oncology
    • 6.6.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Blood Cancer
      • 6.6.2.1. Blood Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. Solid Tumors
      • 6.6.3.1. Solid Tumors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. Others
      • 6.6.4.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. CNS Conditions
    • 6.7.1. CNS Conditions Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Epilepsy
      • 6.7.2.1. Epilepsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Parkinson's Disease (PD)
      • 6.7.3.1. Parkinson's Disease (PD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.4. Huntington's Disease
      • 6.7.4.1. Huntington's Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.5. Stroke
      • 6.7.5.1. Stroke Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.6. Traumatic Brain Injury (TBI)
      • 6.7.6.1. Traumatic Brain Injury (TBI) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.7. Amyotrophic Lateral Sclerosis (ALS)
      • 6.7.7.1. Amyotrophic Lateral Sclerosis (ALS) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.8. Muscle Regeneration
      • 6.7.8.1. Muscle Regeneration Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.9. Others
      • 6.7.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Diabetes
    • 6.8.1. Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.9. Obesity
    • 6.9.1. Obesity Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.10. Cardiovascular Diseases
    • 6.10.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.11. Others
    • 6.11.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. North America Clinical Trials Market: Indication by Study Design Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. North America Clinical Trials Market: Indication by Study Design Movement Analysis
  • 7.3. North America Clinical Trials Market Estimates and Forecasts, by Indication by Study Design, 2021 - 2033 (USD Million)
  • 7.4. Autoimmune/Inflammation
    • 7.4.1. Autoimmune/Inflammation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. Interventional Trials
      • 7.4.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Observational Trials
      • 7.4.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Expanded Access Trials
      • 7.4.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Pain Management
    • 7.5.1. Pain Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. Interventional Trials
      • 7.5.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Observational Trials
      • 7.5.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. Expanded Access Trials
      • 7.5.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Oncology
    • 7.6.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Interventional Trials
      • 7.6.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. Observational Trials
      • 7.6.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. Expanded Access Trials
      • 7.6.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. CNS Conditions
    • 7.7.1. CNS Conditions Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Interventional Trials
      • 7.7.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Observational Trials
      • 7.7.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.4. Expanded Access Trials
      • 7.7.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Diabetes
    • 7.8.1. Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. Interventional Trials
      • 7.8.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Observational Trials
      • 7.8.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. Expanded Access Trials
      • 7.8.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.9. Obesity
    • 7.9.1. Obesity Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.9.2. Interventional Trials
      • 7.9.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.9.3. Observational Trials
      • 7.9.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.9.4. Expanded Access Trials
      • 7.9.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.10. Cardiovascular Diseases
    • 7.10.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.10.2. Interventional Trials
      • 7.10.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.10.3. Observational Trials
      • 7.10.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.10.4. Expanded Access Trials
      • 7.10.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.11. Others
    • 7.11.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.11.2. Interventional Trials
      • 7.11.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.11.3. Observational Trials
      • 7.11.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.11.4. Expanded Access Trials
      • 7.11.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. North America Clinical Trials Market: Service Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. North America Clinical Trials Market: Service Movement Analysis
  • 8.3. North America Clinical Trials Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • 8.4. Protocol Designing
    • 8.4.1. Protocol Designing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Site Identification
    • 8.5.1. Site Identification Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Patient Recruitment
    • 8.6.1. Patient Recruitment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Laboratory Services
    • 8.7.1. Laboratory Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8. Analytical Testing Services
    • 8.8.1. Analytical Testing Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.9. Clinical Trial Data Management Services
    • 8.9.1. Clinical Trial Data Management Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.10. Others
    • 8.10.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. North America Clinical Trials Market: Sponsor Estimates & Trend Analysis

  • 9.1. Segment Dashboard
  • 9.2. North America Clinical Trials Market: Sponsor Movement Analysis
  • 9.3. North America Clinical Trials Market Estimates and Forecasts, by Sponsor, 2021 - 2033 (USD Million)
  • 9.4. Pharmaceutical & Biopharmaceutical Companies
    • 9.4.1. Pharmaceutical & Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5. Medical Device Companies
    • 9.5.1. Medical Device Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6. Others
    • 9.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. North America Clinical Trials Market: Country Estimates & Trend Analysis

  • 10.1. Country Outlook
  • 10.2. North America Clinical Trials Market: Country Movement Analysis
  • 10.3. North America Clinical Trials Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • 10.4. North America
    • 10.4.1. North America Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.4.2. U.S.
      • 10.4.2.1. Key Country Dynamics
      • 10.4.2.2. Competitive Scenario
      • 10.4.2.3. Regulatory Framework
      • 10.4.2.4. U.S. Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.4.3. Canada
      • 10.4.3.1. Key Country Dynamics
      • 10.4.3.2. Competitive Scenario
      • 10.4.3.3. Regulatory Framework
      • 10.4.3.4. Canada Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.4.4. Mexico
      • 10.4.4.1. Key Country Dynamics
      • 10.4.4.2. Competitive Scenario
      • 10.4.4.3. Regulatory Framework
      • 10.4.4.4. Mexico Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 11. Competitive Landscape

  • 11.1. Company Categorization
    • 11.1.1. Innovators
    • 11.1.2. Market Leaders
    • 11.1.3. Emerging Players
  • 11.2. Company Market Assessment Analysis, 2024
  • 11.3. Key Company Profiles
    • 11.3.1. Pfizer Inc.
      • 11.3.1.1. Company Overview
      • 11.3.1.2. Financial Performance
      • 11.3.1.3. Service Benchmarking
      • 11.3.1.4. Strategic Initiatives
    • 11.3.2. Merck & Co., Inc.
      • 11.3.2.1. Company Overview
      • 11.3.2.2. Financial Performance
      • 11.3.2.3. Service Benchmarking
      • 11.3.2.4. Strategic Initiatives
    • 11.3.3. AbbVie Inc.
      • 11.3.3.1. Company Overview
      • 11.3.3.2. Financial Performance
      • 11.3.3.3. Service Benchmarking
      • 11.3.3.4. Strategic Initiatives
    • 11.3.4. Amgen Inc.
      • 11.3.4.1. Company Overview
      • 11.3.4.2. Financial Performance
      • 11.3.4.3. Service Benchmarking
      • 11.3.4.4. Strategic Initiatives
    • 11.3.5. Bristol Myers Squibb
      • 11.3.5.1. Company Overview
      • 11.3.5.2. Financial Performance
      • 11.3.5.3. Service Benchmarking
      • 11.3.5.4. Strategic Initiatives
    • 11.3.6. Gilead Sciences, Inc.
      • 11.3.6.1. Company Overview
      • 11.3.6.2. Financial Performance
      • 11.3.6.3. Service Benchmarking
      • 11.3.6.4. Strategic Initiatives
    • 11.3.7. Eli Lilly and Company
      • 11.3.7.1. Company Overview
      • 11.3.7.2. Financial Performance
      • 11.3.7.3. Service Benchmarking
      • 11.3.7.4. Strategic Initiatives
    • 11.3.8. Biogen Inc.
      • 11.3.8.1. Company Overview
      • 11.3.8.2. Financial Performance
      • 11.3.8.3. Service Benchmarking
      • 11.3.8.4. Strategic Initiatives
    • 11.3.9. Moderna, Inc.
      • 11.3.9.1. Company Overview
      • 11.3.9.2. Financial Performance
      • 11.3.9.3. Service Benchmarking
      • 11.3.9.4. Strategic Initiatives
    • 11.3.10. Labcorp
      • 11.3.10.1. Company Overview
      • 11.3.10.2. Financial Performance
      • 11.3.10.3. Service Benchmarking
      • 11.3.10.4. Strategic Initiatives
    • 11.3.11. IQVIA, Inc.
      • 11.3.11.1. Company Overview
      • 11.3.11.2. Financial Performance
      • 11.3.11.3. Service Benchmarking
      • 11.3.11.4. Strategic Initiatives
    • 11.3.12. Syneos Health
      • 11.3.12.1. Company Overview
      • 11.3.12.2. Financial Performance
      • 11.3.12.3. Service Benchmarking
      • 11.3.12.4. Strategic Initiatives
    • 11.3.13. PAREXEL International Corporation
      • 11.3.13.1. Company Overview
      • 11.3.13.2. Financial Performance
      • 11.3.13.3. Service Benchmarking
      • 11.3.13.4. Strategic Initiatives
    • 11.3.14. ICON Plc
      • 11.3.14.1. Company Overview
      • 11.3.14.2. Financial Performance
      • 11.3.14.3. Service Benchmarking
      • 11.3.14.4. Strategic Initiatives
    • 11.3.15. Thermo Fisher Scientific Inc.
      • 11.3.15.1. Company Overview
      • 11.3.15.2. Financial Performance
      • 11.3.15.3. Service Benchmarking
      • 11.3.15.4. Strategic Initiatives
    • 11.3.16. Charles River Laboratories International Inc.
      • 11.3.16.1. Company Overview
      • 11.3.16.2. Financial Performance
      • 11.3.16.3. Service Benchmarking
      • 11.3.16.4. Strategic Initiatives
    • 11.3.17. Medpace Holdings, Inc.
      • 11.3.17.1. Company Overview
      • 11.3.17.2. Financial Performance
      • 11.3.17.3. Service Benchmarking
      • 11.3.17.4. Strategic Initiatives
    • 11.3.18. Worldwide Clinical Trials
      • 11.3.18.1. Company Overview
      • 11.3.18.2. Financial Performance
      • 11.3.18.3. Service Benchmarking
      • 11.3.18.4. Strategic Initiatives
    • 11.3.19. Clinipace Inc.
      • 11.3.19.1. Company Overview
      • 11.3.19.2. Financial Performance
      • 11.3.19.3. Service Benchmarking
      • 11.3.19.4. Strategic Initiatives
    • 11.3.20. Fortrea
      • 11.3.20.1. Company Overview
      • 11.3.20.2. Financial Performance
      • 11.3.20.3. Service Benchmarking
      • 11.3.20.4. Strategic Initiatives
  • 11.4. List of Other Key Market Players